Fusion Pharmaceuticals To Present Interim Data From Phase 1 Trial Of FPI-1434 in Patients With Solid Tumors Expressing IGF-1R
Portfolio Pulse from Happy Mohamed
Fusion Pharmaceuticals (NASDAQ:FUSN) announced interim data from the Phase 1 trial of FPI-1434 in patients with solid tumors expressing IGF-1R. The data showed that pre-administration of cold antibody prior to administering radiolabeled FPI-1434 has the potential to enhance the therapeutic index and improve the safety profile compared to hot-only dosing.
June 26, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fusion Pharmaceuticals' interim data from the Phase 1 trial of FPI-1434 shows potential to improve the therapeutic index and safety profile, which could positively impact the company's stock price.
The interim data from the Phase 1 trial of FPI-1434 demonstrates potential improvements in the therapeutic index and safety profile. This could lead to increased interest in the company's stock and a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100